Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Ankylosing Spondylitis Market

Ankylosing Spondylitis Market Trends

Report ID: GMI10134
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Ankylosing Spondylitis Market Trends

Increasing cases of ankylosing spondylitis (AS) significantly drives the growth of the market.
As per a study published by European Alliance of Associations for Rheumatology, EULAR 2024, ankylosing spondylitis (AS) is among the most common forms of immune-mediated arthritis, affecting ~0.5% of the population worldwide, except for people of African ancestry where its prevalence is much lower. This surge in prevalence necessitates a higher demand for effective treatments, including biologics, non-steroidal anti-inflammatory drugs (NSAIDs), and physical therapy.
Consequently, pharmaceutical companies are investing in research and development to introduce innovative therapies, further propelling market expansion.
Moreover, increased patient awareness and access to healthcare services contribute to early diagnosis and treatment, enhancing the overall management of the disease and fueling market growth

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global ankylosing spondylitis industry was valued at USD 5.9 billion in 2023 and is anticipated to register 8.2% CAGR between 2024 and 2032, driven by increasing advancements in treatment options.

The hospital pharmacies segment is expected to witness 7.9% CAGR through 2032, driven by hospitals' access to advanced therapies for conditions like ankylosing spondylitis.

North America ankylosing spondylitis market is expected to reach USD 4.8 billion by 2032 due to advanced healthcare infrastructure and favorable regulatory environments.

AbbVie, Inc., Amgen, Inc., Bayer AG, Eli Lilly and Company, Horizon Pharma, Janssen Biotech, Inc., Merck & Co., Inc., Novartis AG, PRIMUS PHARMACEUTICALS, Pfizer, Inc., Sandoz Group AG, and UCB, Inc.